Holen Sie sich die Stockscreener-App
131.06
0.68%
-0.90
Handel nachbörslich:
131.06
Schlusskurs vom Vortag:
$131.96
Offen:
$131.87
24-Stunden-Volumen:
1.46M
Relative Volume:
1.20
Marktkapitalisierung:
$7.39B
Einnahmen:
$763.34M
Nettoeinkommen (Verlust:
$51.40M
KGV:
144.28
EPS:
0.9084
Netto-Cashflow:
$104.46M
1W Leistung:
-9.92%
1M Leistung:
-10.85%
6M Leistung:
-19.90%
1J Leistung:
+7.66%
1-Tages-Spanne:
$130.03
$133.35
1-Wochen-Bereich:
$129.00
$148.37
52-Wochen-Spanne:
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
131.06 | 7.44B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
356.83 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
158.92 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.70 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.28 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.08 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-01 | Eingeleitet | HSBC Securities | Buy |
| 2025-09-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-29 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | Evercore ISI | In-line |
| 2025-02-10 | Eingeleitet | TD Cowen | Buy |
| 2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
| 2019-08-23 | Fortgesetzt | Stephens | Overweight |
| 2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Hochstufung | CL King | Neutral → Buy |
| 2018-11-12 | Herabstufung | CL King | Buy → Neutral |
| 2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
| 2017-12-08 | Eingeleitet | Citigroup | Buy |
| 2017-12-05 | Eingeleitet | JP Morgan | Overweight |
| 2017-11-13 | Eingeleitet | CL King | Buy |
| 2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Eingeleitet | William Blair | Outperform |
| 2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Repligen Corp|Price:131.970|Chg%:-5.630 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com India
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Repligen Corp To Acquire BioLife Solutions Transcript - GuruFocus
Repligen to buy cell therapy maker BioLife in $1.5 billion deal - MSN
Repligen to acquire BioLife Solutions for $1.5 billion - Investing.com
BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies - Stock Titan
A Look at Repligen Corp (RGEN) After 5.9% Decline -- GF Value $1 - GuruFocus
Why Repligen (RGEN) Stock Is Trading Lower Today - Yahoo Finance
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in cash and stock merger - Stock Titan
Form 4 Repligen Corporation For: 17 July By Investing.com - Investing.com South Africa
Repligen CFO Jason K Garland sells $79,500 in stock - Investing.com UK
Repligen CFO Jason K Garland sells $79,500 in stock By Investing.com - Investing.com Nigeria
Repligen CFO Jason Garland Sells 530 Shares Under Pre-Arranged Rule 10b5-1 Trading Plan - Kalkine Media
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):